VeriMommyricetin sesquicaprylate은 임신 중 안전한가요?
No harmonised CLP classification, no SCCS/CIR reproductive safety assessment located for this ingredient, and the parent compound myricetin lacks consistent evidence of human teratogenicity; published literature on myricetin mainly reports biological activity and some protective/reparative effects in animal models rather than reproductive hazard. Topical esters are expected to have low but measurable dermal absorption; therefore exposure during pregnancy is low but not nil. (Sources: PubMed review on myricetin; cosmetic ingredient databases listing myricetin sesquicaprylate; EWG myricetin page).
Related ingredients
Frequently asked questions
- myricetin sesquicaprylate은 임신 중 안전한가요?
- No harmonised CLP classification, no SCCS/CIR reproductive safety assessment located for this ingredient, and the parent compound myricetin lacks consistent evidence of human teratogenicity; published literature on myricetin mainly reports biological activity and some protective/reparative effects in animal models rather than reproductive hazard. Topical esters are expected to have low but measurable dermal absorption; therefore exposure during pregnancy is low but not nil. (Sources: PubMed review on myricetin; cosmetic ingredient databases listing myricetin sesquicaprylate; EWG myricetin page).
- myricetin sesquicaprylate은 모유 수유 중 안전한가요?
- No data found showing reproductive or lactation-specific toxicity or harmonised classification for myricetin sesquicaprylate. Dermal use in nursing parent is expected to give low but measurable exposure; transfer into breastmilk after topical use is unlikely but not studied for this ester specifically.
- myricetin sesquicaprylate은 아기 피부에 안전한가요?
- No infant-specific safety studies located for the sesquicaprylate ester. Because infants (0–3 yr) have higher skin permeability and surface‑area‑to‑weight ratio, exposure score is increased by +1 compared with adults (adult e=1 → infant e=2). No evidence was found to indicate the ingredient is a developmental toxin or endocrine disruptor at expected topical exposures.
- VeriMom은 myricetin sesquicaprylate을 어떻게 평가하나요?
- VeriMom은 EU CosIng, ECHA 분류, PubMed 연구를 기반으로 myricetin sesquicaprylate을 93/100 (알려진 위험 없음)로 평가합니다.
- 임신 중 myricetin sesquicaprylate 대체 안전 성분은?
- 유사한 기능을 가진 알려진 위험이 없는 대체 성분 목록을 확인하세요.
모든 성분표를 2초 만에 확인
VeriMom 무료 다운로드 — 어떤 제품이든 스캔해 임신 중 안전 점수를 즉시 확인하세요.
의료 면책 조항
이 정보는 교육 목적으로만 제공되며 의학적 조언을 구성하지 않습니다. 안전 점수는 공개적으로 이용 가능한 데이터를 기반으로 하며 모든 위험을 반영하지 않을 수 있습니다. 임신 중 또는 수유 중 제품을 사용하기 전에 항상 의료 전문가와 상담하십시오.